Literature DB >> 14566464

[Rapidly progressive glomerulonephritis:classification, pathogenesis and clinical management].

R Birck1, F J Van Der Woude.   

Abstract

Rapidly progressive glomerulonephritides (RPGN) belong to a heterogeneous group of inflammatory kidney diseases which are commonly associated with systemic vasculitic syndromes. Renal histology is characterized by necrotizing lesions within the glomerual tuft and extracapillary proliferation, in most cases leading rapidly to renal failure. The etiology and pathogenesis are only partly elucidated. Since irreversible renal scaring develops within days to weeks, RPGN represent a nephrological emergency necessitating urgent diagnostic evaluation and rapid institution of effective therapy. New onset nephritic sediment combined with concomitantly deteriorating excretory renal function should lead to immediate nephrological consultation. Autoimmune serology and particularly renal biopsy are of the utmost importance for rapid diagnosis. Most forms of RPGN are treated with immunosuppressive regimens which generally consist of high dose steroids in combination with the alkylating agent cyclophosphamide. Some forms also require the use of plasma exchange therapy. Rapid diagnosis and early therapy improves both renal and overall outcome in the affected patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566464     DOI: 10.1007/s00108-003-1025-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  66 in total

Review 1.  Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis.

Authors:  G Gaskin; C D Pusey
Journal:  Ther Apher       Date:  2001-06

Review 2.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

3.  Taking anti-neutrophil cytoplasmic antibody (ANCA) testing beyond the limits.

Authors:  Fokko J Van Der Woude
Journal:  Nephrol Dial Transplant       Date:  2002-12       Impact factor: 5.992

Review 4.  ANCA are pathogenic--oh yes they are!

Authors:  Ronald J Falk; J Charles Jennette
Journal:  J Am Soc Nephrol       Date:  2002-07       Impact factor: 10.121

5.  Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.

Authors:  J B Levy; A N Turner; A J Rees; C D Pusey
Journal:  Ann Intern Med       Date:  2001-06-05       Impact factor: 25.391

6.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.

Authors:  E C Hagen; M R Daha; J Hermans; K Andrassy; E Csernok; G Gaskin; P Lesavre; J Lüdemann; N Rasmussen; R A Sinico; A Wiik; F J van der Woude
Journal:  Kidney Int       Date:  1998-03       Impact factor: 10.612

7.  The macrophagen in human rapidly progressive glomerulonephritis.

Authors:  R C Atkins; S R Holdsworth; E F Glasgow; F E Matthews
Journal:  Lancet       Date:  1976-04-17       Impact factor: 79.321

8.  Rapidly progressive glomerulonephritis: analysis of prevalence and clinical course.

Authors:  K Andrassy; S Küster; R Waldherr; E Ritz
Journal:  Nephron       Date:  1991       Impact factor: 2.847

9.  Anti-glomerular basement membrane nephritis after extracorporeal shock wave lithotripsy.

Authors:  I Iwamoto; S Yonekawa; T Takeda; M Sakaguchi; T Ohno; H Tanaka; H Hasegawa; A Imada; A Horiuchi; T Umekawa; T Kurita
Journal:  Am J Nephrol       Date:  1998       Impact factor: 3.754

10.  Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease.

Authors:  X Bosch; E Mirapeix; J Font; X Borrellas; R Rodríguez; A López-Soto; M Ingelmo; L Revert
Journal:  Clin Nephrol       Date:  1991-09       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.